Anas Younes, MD | Authors

Articles

Results for the Combination of Nivolumab and Ibrutinib in Non-Hodgkin Lymphoma and CLL

March 14, 2018

Anas Younes, MD, chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center, discusses results from a trial studying the combination of nivolumab and ibrutinib for the treatment of patients with relapsed non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Using PET or CT for Staging Patients with Follicular Lymphoma

March 07, 2018

Anas Younes, MD, chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center, discusses current research for staging patients with follicular lymphoma. In order to design new clinical trials, researchers must have reliable predictors of overall survival and progression-free survival in patients.

Results for Atezolizumab, Obinutuzumab, and Bendamustine in Follicular Lymphoma

January 05, 2018

Anas Younes, MD, Chief of Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the interim analysis of a study exploring the safety and efficacy of atezolizumab (Tecentriq) in combination with obinutuzumab (Gazya) and bendamustine in patients with previously untreated follicular lymphoma.

ABVD Versus A+AVD as Front-Line Treatment in Hodgkin Lymphoma

July 03, 2014

Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses a phase III trial of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as front-line treatment for advanced classical Hodgkin lymphoma.